Concepts (229)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 18 | 2019 | 173 | 5.380 |
Why?
|
| Antineoplastic Agents | 13 | 2019 | 546 | 3.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2018 | 401 | 1.630 |
Why?
|
| Apoptosis | 8 | 2019 | 337 | 1.140 |
Why?
|
| Neoplasms | 3 | 2018 | 608 | 1.130 |
Why?
|
| Fluorodeoxyuridylate | 3 | 2016 | 23 | 1.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2017 | 39 | 1.080 |
Why?
|
| Cytarabine | 5 | 2018 | 52 | 0.980 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2014 | 69 | 0.960 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 162 | 0.880 |
Why?
|
| Mitochondria | 4 | 2019 | 174 | 0.870 |
Why?
|
| Sulfides | 4 | 2018 | 24 | 0.850 |
Why?
|
| Caprylates | 4 | 2018 | 25 | 0.850 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2019 | 89 | 0.680 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 711 | 0.670 |
Why?
|
| Resuscitation Orders | 1 | 2017 | 11 | 0.630 |
Why?
|
| Salvage Therapy | 2 | 2015 | 118 | 0.620 |
Why?
|
| Glycerophosphates | 1 | 2017 | 4 | 0.620 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2014 | 22 | 0.610 |
Why?
|
| Deoxycytidine | 1 | 2017 | 63 | 0.600 |
Why?
|
| Neoplasm Proteins | 2 | 2014 | 141 | 0.580 |
Why?
|
| Leukemia | 2 | 2014 | 36 | 0.580 |
Why?
|
| Intensive Care Units | 1 | 2017 | 118 | 0.580 |
Why?
|
| Humans | 29 | 2019 | 29013 | 0.570 |
Why?
|
| Nucleosides | 1 | 2016 | 9 | 0.560 |
Why?
|
| Aged | 16 | 2018 | 9462 | 0.540 |
Why?
|
| Thymidylate Synthase | 2 | 2012 | 13 | 0.540 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 2012 | 9 | 0.540 |
Why?
|
| Mice | 9 | 2018 | 2368 | 0.530 |
Why?
|
| Animals | 12 | 2018 | 7297 | 0.530 |
Why?
|
| Cytogenetics | 1 | 2015 | 6 | 0.520 |
Why?
|
| Fas Ligand Protein | 1 | 2014 | 7 | 0.520 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 17 | 0.510 |
Why?
|
| Membrane Microdomains | 1 | 2014 | 24 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 83 | 0.510 |
Why?
|
| Lipids | 1 | 2016 | 208 | 0.500 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 28 | 0.500 |
Why?
|
| Pyrimidines | 1 | 2014 | 60 | 0.490 |
Why?
|
| DNA Damage | 4 | 2017 | 88 | 0.480 |
Why?
|
| Azacitidine | 1 | 2013 | 28 | 0.480 |
Why?
|
| Middle Aged | 15 | 2018 | 10805 | 0.460 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 4 | 0.440 |
Why?
|
| DNA Methylation | 1 | 2013 | 129 | 0.440 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2012 | 23 | 0.440 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 33 | 0.440 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 90 | 0.420 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2012 | 72 | 0.420 |
Why?
|
| Treatment Outcome | 7 | 2018 | 3099 | 0.420 |
Why?
|
| Aged, 80 and over | 7 | 2017 | 3712 | 0.420 |
Why?
|
| Disease Models, Animal | 5 | 2014 | 980 | 0.410 |
Why?
|
| Female | 17 | 2018 | 18114 | 0.410 |
Why?
|
| Tandem Repeat Sequences | 1 | 2011 | 5 | 0.400 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 16 | 0.400 |
Why?
|
| Leukemia, Myeloid | 1 | 2011 | 24 | 0.400 |
Why?
|
| Membrane Proteins | 1 | 2012 | 256 | 0.390 |
Why?
|
| Adult | 9 | 2018 | 8391 | 0.390 |
Why?
|
| Cell Line, Tumor | 5 | 2017 | 680 | 0.380 |
Why?
|
| Remission Induction | 3 | 2015 | 78 | 0.380 |
Why?
|
| Male | 16 | 2018 | 17768 | 0.370 |
Why?
|
| Doxorubicin | 3 | 2017 | 55 | 0.350 |
Why?
|
| Retrospective Studies | 6 | 2018 | 3107 | 0.300 |
Why?
|
| Mitoxantrone | 2 | 2018 | 17 | 0.300 |
Why?
|
| Recurrence | 2 | 2018 | 235 | 0.280 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 76 | 0.260 |
Why?
|
| Neoplasm Staging | 2 | 2018 | 436 | 0.260 |
Why?
|
| Age Factors | 4 | 2018 | 1105 | 0.250 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 246 | 0.250 |
Why?
|
| Mice, Transgenic | 2 | 2017 | 249 | 0.240 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2003 | 1 | 0.230 |
Why?
|
| RNA Polymerase II | 1 | 2003 | 2 | 0.230 |
Why?
|
| Genes, Regulator | 1 | 2003 | 6 | 0.230 |
Why?
|
| Guanosine Triphosphate | 1 | 2003 | 8 | 0.230 |
Why?
|
| Comorbidity | 5 | 2018 | 539 | 0.220 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 136 | 0.220 |
Why?
|
| Geriatric Assessment | 3 | 2016 | 355 | 0.210 |
Why?
|
| Survival Analysis | 2 | 2015 | 440 | 0.210 |
Why?
|
| Electron Transport | 2 | 2019 | 16 | 0.210 |
Why?
|
| Hyperglycemia | 2 | 2018 | 82 | 0.200 |
Why?
|
| RNA, Messenger | 1 | 2003 | 514 | 0.200 |
Why?
|
| Young Adult | 2 | 2018 | 2398 | 0.180 |
Why?
|
| Prognosis | 5 | 2018 | 1362 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 31 | 0.170 |
Why?
|
| Heme | 1 | 2019 | 60 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2018 | 573 | 0.170 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2018 | 8 | 0.170 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 6 | 0.160 |
Why?
|
| Survival Rate | 3 | 2018 | 795 | 0.160 |
Why?
|
| Cell Respiration | 1 | 2018 | 21 | 0.160 |
Why?
|
| Protein Biosynthesis | 1 | 2018 | 46 | 0.160 |
Why?
|
| Retreatment | 1 | 2018 | 40 | 0.160 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 706 | 0.160 |
Why?
|
| HL-60 Cells | 2 | 2014 | 14 | 0.160 |
Why?
|
| Bone Marrow | 1 | 2018 | 60 | 0.160 |
Why?
|
| Philadelphia Chromosome | 1 | 2017 | 4 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2017 | 60 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 50 | 0.150 |
Why?
|
| Protein Kinase C | 1 | 2017 | 37 | 0.150 |
Why?
|
| Patient Transfer | 1 | 2017 | 34 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 23 | 0.150 |
Why?
|
| Oxygen Consumption | 1 | 2018 | 138 | 0.150 |
Why?
|
| Splenomegaly | 1 | 2016 | 6 | 0.150 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 9 | 0.150 |
Why?
|
| Biopsy | 1 | 2018 | 241 | 0.150 |
Why?
|
| Cosmic Radiation | 1 | 2016 | 13 | 0.150 |
Why?
|
| Random Allocation | 1 | 2017 | 212 | 0.150 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2016 | 14 | 0.150 |
Why?
|
| Cell Line | 1 | 2018 | 449 | 0.150 |
Why?
|
| DNA, Neoplasm | 2 | 2013 | 58 | 0.140 |
Why?
|
| Radiation Injuries | 1 | 2016 | 67 | 0.140 |
Why?
|
| Biological Availability | 1 | 2016 | 21 | 0.140 |
Why?
|
| Tumor Cells, Cultured | 2 | 2016 | 158 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2018 | 465 | 0.140 |
Why?
|
| Depression | 2 | 2016 | 378 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2017 | 131 | 0.140 |
Why?
|
| Asparaginase | 1 | 2015 | 5 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 641 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 237 | 0.130 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 113 | 0.130 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 12 | 0.130 |
Why?
|
| Ribonucleotide Reductases | 1 | 2014 | 6 | 0.130 |
Why?
|
| Cognition | 2 | 2016 | 524 | 0.130 |
Why?
|
| Lung | 1 | 2016 | 233 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 58 | 0.130 |
Why?
|
| Polypharmacy | 1 | 2014 | 20 | 0.120 |
Why?
|
| Oligonucleotides | 1 | 2014 | 27 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 301 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 95 | 0.120 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2011 | 6 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 160 | 0.120 |
Why?
|
| Drug Evaluation | 1 | 2013 | 10 | 0.120 |
Why?
|
| Stem Cells | 1 | 2016 | 292 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2016 | 224 | 0.120 |
Why?
|
| Hospitalization | 2 | 2018 | 417 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2015 | 331 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 172 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2012 | 2 | 0.110 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2012 | 6 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 629 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 17 | 0.110 |
Why?
|
| DNA Replication | 1 | 2012 | 23 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 8 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 384 | 0.110 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 50 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 48 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 298 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2012 | 47 | 0.110 |
Why?
|
| Histones | 1 | 2012 | 49 | 0.110 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 23 | 0.110 |
Why?
|
| Substrate Specificity | 1 | 2012 | 84 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 113 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2012 | 172 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 3 | 0.100 |
Why?
|
| Gene Duplication | 1 | 2011 | 5 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 11 | 0.100 |
Why?
|
| Niacinamide | 1 | 2011 | 8 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 836 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2014 | 666 | 0.100 |
Why?
|
| Pyridines | 1 | 2011 | 78 | 0.100 |
Why?
|
| RNA Interference | 1 | 2011 | 76 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 248 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 239 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2011 | 281 | 0.090 |
Why?
|
| Risk Factors | 2 | 2015 | 3509 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 871 | 0.090 |
Why?
|
| Time Factors | 1 | 2015 | 1997 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 1007 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1374 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2016 | 2010 | 0.060 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 15 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2003 | 14 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2003 | 40 | 0.060 |
Why?
|
| Binding Sites | 1 | 2003 | 125 | 0.060 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2012 | 15 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 142 | 0.050 |
Why?
|
| DNA | 1 | 2003 | 204 | 0.050 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2019 | 6 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 11 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2019 | 15 | 0.040 |
Why?
|
| Mitochondrial Membranes | 1 | 2019 | 21 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2019 | 42 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 65 | 0.040 |
Why?
|
| Hypoalbuminemia | 1 | 2017 | 9 | 0.040 |
Why?
|
| Lymphopenia | 1 | 2017 | 11 | 0.040 |
Why?
|
| Leucovorin | 1 | 2017 | 20 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2017 | 14 | 0.040 |
Why?
|
| Neutropenia | 1 | 2017 | 23 | 0.040 |
Why?
|
| Sensation Disorders | 1 | 2017 | 19 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 32 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 56 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 42 | 0.040 |
Why?
|
| Camptothecin | 1 | 2017 | 48 | 0.040 |
Why?
|
| Abdominal Pain | 1 | 2017 | 40 | 0.040 |
Why?
|
| Body Burden | 1 | 2016 | 6 | 0.040 |
Why?
|
| Astronauts | 1 | 2016 | 7 | 0.040 |
Why?
|
| Anemia | 1 | 2017 | 55 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2017 | 73 | 0.040 |
Why?
|
| Topotecan | 1 | 2016 | 15 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2016 | 72 | 0.040 |
Why?
|
| Genome, Human | 1 | 2016 | 129 | 0.040 |
Why?
|
| Physical Examination | 1 | 2016 | 82 | 0.040 |
Why?
|
| Mental Health | 1 | 2016 | 102 | 0.030 |
Why?
|
| Sepsis | 1 | 2017 | 146 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 360 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2016 | 168 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2016 | 187 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 145 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 337 | 0.030 |
Why?
|
| Logistic Models | 1 | 2015 | 725 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 16 | 0.030 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2012 | 2 | 0.030 |
Why?
|
| Thymine | 1 | 2012 | 6 | 0.030 |
Why?
|
| S Phase | 1 | 2012 | 11 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2013 | 59 | 0.030 |
Why?
|
| Alkaloids | 1 | 2012 | 9 | 0.030 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2012 | 21 | 0.030 |
Why?
|
| Nursing Assessment | 1 | 2011 | 11 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 636 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 784 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 262 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 310 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 210 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2009 | 7 | 0.020 |
Why?
|
| Genes, ras | 1 | 2009 | 26 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2009 | 16 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 249 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 320 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 735 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 1674 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 1422 | 0.020 |
Why?
|